** Shares of medical device maker Tandem Diabetes Care TNDM.O down 24% at $25.50
** Company late on Wednesday forecast 2025 sales between $997 mln and $1.007 bln vs. analysts' average estimate of $1.004 billion, according to data compiled by LSEG
** Says "muted seasonality" and "shipping delays" led to softness in demand for co's insulin pumps towards the end of Q4 and expects salesforce disruptions -TNDM
** The 2025 outlook reflects the seasonal trends extending into Q1 - RBC Capital analysts
** "What will likely cause investor consternation is the lower-than-anticipated Q1 2025 revenue guidance and the implied ramp through the rest of the year" -Brokerage Citi
** Company sees Q1 sales to be about $219 million to $224 million compared to analysts' estimate of $221 million
** TNDM has risen 16.4% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.